Patient Advocacy Leaders and Drug Development Industry Network

Welcome to PALADIN,  a first-of-its-kind consortium dedicated to transforming the pace of medicines development through optimizing patient advocacy group–industry collaboration.

We are a pre-competitive, disease-agnostic membership community working together to create consensus-based resources, guidelines and solutions that will transform how patient advocacy groups, pharmaceutical and biotechnology companies collaborate in the future.

home page team collaborating image

“We are thrilled to partner with an esteemed group of industry and patient advocacy organizations on this consortium, which was born out of our deep-rooted conviction for patient-centered R&D. Together, we have an opportunity to identify ways to reduce the time it takes to develop new medicines – bringing new treatment options to patients sooner and giving them hope for the future.”

Victoria DiBiaso,
VP, Global Head Patient Informed Development & Health Value Translation at Sanofi, Chair, PALADIN Executive Committee

View Our New Resources

1. PALADIN Playbook – best practices, guidance, and tools for effective PAG-Industry collaboration written by PALADIN members.

2. Resource Repository – curation of best-in-class resources templates, and toolkits from across the PAG and Industry community.

In The Media

Patients as Partners 2024: Optimizing “How” Patient Advocacy and Biopharma can Best Collaborate to Transform the Pace of Medicines Development

Press Release: PALADIN Releases Playbook & Resource Repository to Support More Effective Patient Advocacy Group & Biopharmaceutical Company Collaborations

DIA 2023: PALADIN Brings Patient Advocacy and Industry Together

Our Why

The last decade has seen a proliferation in the number of investigational therapies, companies sponsoring active clinical trials, and with that, the number of collaborations between patient advocacy groups and biopharmaceutical companies. Collaborations aim to:

  • Reach and recruit patients
  • Help shape clinical development plans
  • Ensure outcomes relevant to patient communities are reflected in drug development activity
  • Support access to clinical trials for historically underserved communities

While well-intentioned, with few exceptions, collaborations between patient advocacy groups and industry have been limited in their effectiveness in making clinical research faster and more efficient. 

PALADIN aims to standardize and structure these R&D-driven collaborations to optimize their impact.

Have additional questions about our efforts?

Click here to contact us.

Select Language »